X
<

What Allergan's Latest Developments Tell Us

PART:
1 2 3 4 5 6 7
Part 6
What Allergan's Latest Developments Tell Us PART 6 OF 7

A Closer Look at Allergan’s International Business

AGN’s International segment

Allergan’s (AGN) International segment represents the total revenues from the sales of branded products and aesthetics products in markets outside the US. The segment reported a 13.4% YoY (year-over-year) rise in revenues to $858.5 million in 2Q17, compared with $757.0 million in 2Q16.

A Closer Look at Allergan’s International Business

Interested in AGN? Don't miss the next report.

Receive e-mail alerts for new research on AGN

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Franchise revenues

This segment’s eye care franchise includes Refresh and Restasis for dry eyes as well as Alphagan, Lumigan, and Combigan for glaucoma. Other eye care products include Acular LS, Acuvail, Botox, Elestat, and Pred Forte. This franchise reported 1% YoY growth in revenues to $322.0 million in 2Q17, compared with $318.7 million in 2Q16.

Facial aesthetics including Botox cosmetic products, Juvederm products, and other products like Kybella and Latisse reported a 19.5% YoY rise in revenues to $287.5 million in 2Q17, compared with $240.6 million in 2Q16.

Plastic surgery products including Natrelle breast augmentation products, silicone-filled implants, saline-filled implants, and breast reconstruction products reported a 2.9% YoY rise in revenues to $41.5 million in 2Q17, compared with $40.3 million in 2Q16.

Other product revenues

Skincare products including Prevage and SkinMedica products reported revenues of $2.7 million in 2Q17. Regenerative medicines reported revenues of $3.6 million in 2Q17, while body contouring reported revenues of $22.7 million.

Other therapeutics including Botox products for urologic and neurosciences, Asacol, and Constella products reported a 7.2% YoY rise in revenues to $151.2 million in 2Q17, compared with $141.1 million in 2Q16.

To divest company-specific risks, investors can consider ETFs like VanEck Vectors Morningstar Wide Moat ETF (MOAT), which has 2.4% of its total assets in Allergan MOAT also has 2.5% in Eli Lilly (LLY), 2.7% in Amgen (AMGN), and 3.0% in Biogen (BIIB).

X

Please select a profession that best describes you: